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Abstract
Background: Prostate cancer (CaP) is one of the most relevant causes of cancer death in Western Countries. Although
detection of CaP at early curable stage is highly desirable, actual screening methods present limitations and new molecular
approaches are needed. Gene expression analysis increases our knowledge about the biology of CaP and may render novel
molecular tools, but the identification of accurate biomarkers for reliable molecular diagnosis is a real challenge. We
describe here the diagnostic power of a novel 8-genes signature: ornithine decarboxylase (ODC), ornithine decarboxylase
antizyme (OAZ), adenosylmethionine decarboxylase (AdoMetDC), spermidine/spermine N(1)-acetyltransferase (SSAT), histone
H3 (H3), growth arrest specific gene (GAS1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Clusterin (CLU) in
tumour detection/classification of human CaP.
Methodology/Principal Findings: The 8-gene signature was detected by retrotranscription real-time quantitative PCR (RT-
qPCR) in frozen prostate surgical specimens obtained from 41 patients diagnosed with CaP and recommended to undergo
radical prostatectomy (RP). No therapy was given to patients at any time before RP. The bio-bank used for the study
consisted of 66 specimens: 44 were benign-CaP paired from the same patient. Thirty-five were classified as benign and 31 as
CaP after final pathological examination. Only molecular data were used for classification of specimens. The Nearest
Neighbour (NN) classifier was used in order to discriminate CaP from benign tissue. Validation of final results was obtained
with 10-fold crossvalidation procedure. CaP versus benign specimens were discriminated with (8065)% accuracy, (8166)%
sensitivity and (7867)% specificity. The method also correctly classified 71% of patients with Gleason score,7 versus$7, an
important predictor of final outcome.
Conclusions/Significance: The method showed high sensitivity in a collection of specimens in which a significant portion of
the total (13/31, equal to 42%) was considered CaP on the basis of having less than 15% of cancer cells. This result supports
the notion of the ‘‘cancer field effect’’, in which transformed cells extend beyond morphologically evident tumour. The
molecular diagnosis method here described is objective and less subjected to human error. Although further confirmations
are needed, this method posses the potential to enhance conventional diagnosis.
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Introduction
Prostate cancer (CaP) is believed to become the most relevant
cause of cancer death in the Western Countries in the near future
because its incidence increases rapidly with age. Since prognosis is
generally unfavourable when disease is no longer organ-confined,
detection of CaP at an early curable stage is highly desirable, but
unfortunately available methods such as serum Prostate Specific
Antigen (PSA) present limitations [1]. The diagnosis of CaP is
conventionally obtained by saturation prostate biopsy and
morphological examination of tissue sections. This method is
reliable, but requires careful training. Nevertheless, intra- and
inter-observer incongruities may occur. In principle, molecular
diagnosis would be more objective and, hopefully, significantly less
subjected to human error if obtained with reliable methods. But
the ideal method should also be fast, standardized and
economically convenient. Such achievement is indeed possible in
theory, but results published are not completely satisfactory yet,
also because they are usually based on a conventional approach
with takes advantage of a single molecular predictor significantly
up- or down-regulated in the cancer specimen versus benign
control. A major obstacle to this goal is that the molecular events
causing CaP onset and progression are still far from being
completely revealed: very few well known oncogenes or tumor-
suppressors have been clearly linked to prostate tumorigenesis, and
for this reason CaP is still considered an elusive disease. Therefore,
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new molecular approaches for early screening and diagnosis are
urgently needed.
Gene expression analysis was recently used to increase our
knowledge about the biology of CaP [2]. Gene signatures at RNA
level are determined and often used as predictors to model
clinically relevant information (e.g. prognosis, survival time,
sensitivity to drugs, etc.). To this aim, final conclusions on the
classification power of the gene signature studied are entirely
drawn on the basis of the molecular data obtained at transcrip-
tional level by using methods such as DNA microarray or RT q-
PCR. By Northern blot analysis, we have previously identified 8
informative genes whose expression changes on the basis of the
presence of CaP malignancy in humans [3]. In a 5-year follow-up
study, we also showed that the levels of expression of this panel of
genes strongly correlate with differentiation and final outcome
(prognosis) of CaP patients. This result was obtained by combining
molecular data with standard clinical information [4]. But in our
mind the real challenge was to detect CaP by means of molecular
tools alone. Although the study of specifically altered gene
expression during CaP tumourigenesis is a difficult task, the
scientific information that will ultimately be obtained is an
important reward, leading to a better understanding of the
molecular basis of the disease which may lead to better methods
for diagnosis and therapy. This is particularly important when
considering the heterogeneity of CaP and the variability of clinical
progression, with some patients presenting with slow growing
indolent tumours and other patients having a disease that is
rapidly progressive.
The signature that we have identified is made of 4 metabolically
related genes, ODC, OAZ, AdoMetDC, SSAT, the regulatory genes of
the polyamine metabolism, 2 genes related to cell cycle
progression, H3 and GAS1, specific markers of S- and G0-phases,
respectively [5,6], GAPDH, an enzyme of the glycolitic pathway,
and CLU an enigmatic protein whose biological role is still a
matter of debate.
CLU, also known as SGP-2, TRPM-2 or ApoJ, is highly over-
expressed during prostate gland involution and remodelling [7,8].
Although there is a general consensus about the involvement of CLU
in regulating cell death, its specific role in the apoptotic process is still
controversial, as well as in cell transformation. More specifically, its
level of expression and regulation during CaP onset and progression
is debated [9,10]. A better understanding of this issue is of particular
importance not only because of the above considerations, but also
because a clinical trial aimed at silencing CLU gene by antisense
oligonucleotides in CaP patients is currently ongoing [11]. As a
matter of fact, we and others have found that CLU is down-regulated
during CaP progression [12–15], suggesting that it might act as a
tumour-suppressor factor [16,17].
Concerning the gene signature described here, all of the genes
studied have previously shown strictly related shifts in co-
expression during CaP progression [3]. Specific alteration of
transcription of the regulatory enzymes of polyamine metabolism
during CaP progression has also been validated by meta-analysis
of microarrays [18]. In the TRAMP mice model of CaP
progression, our gene signature alone as determined by RT-
qPCR, besides discriminating CaP from benign tissue, also
predicted individual response to treatment with Green Tea
Catechins (GTCs) [19]. Other individual marker genes have been
found of proven validity in this field, such as a-methylacyl
coenzyme A racemase (AMACR) [20,21] or Prostate Cancer
Antigen 3 (DD3/PCA3) [22], but at the moment no relationship
between the expression level of PCA3 and tumour grade or staging
was found yet. Our gene signature is made of informative genes
some of which are well known to play important roles in the
physiology of prostate cells, such as the genes coding for regulatory
proteins of polyamine metabolism [23] and CLU [7].
The aim of our study was to show that our gene signature alone
enhances the sensitivity and the specificity of molecular diagnosis of
CaP when compared to single marker identification. We used
histopathologic classification of fixed tissues specimens as final
reference, as usually done in similar circumstances [24,25]. The 8-
gene model was detected by RT-qPCR in frozen tissue specimens
obtained at Radical Prostatectomy (RP). Classification of tissue
specimens (i.e. presence or absence of tumour) was performed
without other pathological or clinical data. Furthermore, molecular
data were used for sub-classification of tissue specimens with regard
to Gleason score, age and total serum PSA of the patient at RP.
For specimen classification we used the Nearest Neighbour (NN)
classifier, a statistical multi-factorial analysis tool known to perform
well specifically for cancer classification when compared with
other methods. For validation of classification performance, we
used the 10-fold cross validation procedure, repeated 100 times
with different sub-samplings in order to estimate the mean
performance of the signature and the confidence interval (results
are expressed as mean695% confidence interval, approximately
corresponding to 2 standard deviations).
Results
The tissue specimens bio-bank
The bio-bank consisted of a collection of 66 human specimens,
see Table 1, matching our eligibility criteria for the study: i)
pathological evidence of presence or absence of CaP in the frozen
pre- and post-RNA sections; ii) benign specimens free of prostate
intraepithelial neoplasia (PIN) lesions or tumour invasion, taken
very far away (i.e. in different areas of the prostate, ideally in the
controlateral sextant) from the neoplastic lesion; iii) CaP specimens
having a cancer cell content covering at least 5% of the whole
section area; iv) good yield and high quality of RNA preparation.
Among these, 44 specimens were CaP-benign paired specimens
obtained from the same patient. Thirthy-five specimens were
classified as benign by the pathologist, while 31 were CaP.
How to get molecular and morphological data from the
same tissue specimen: the ‘‘sandwich’’ method
To obtain a direct comparison between molecular data and
pathological classification we developed a ‘‘sandwich’’ method (see
Figure 1 and Methods: Prostate Tissue Specimens Collection and
Handling). RNA extraction yielded an average of 50–60 mg of
total RNA from 20 mg of human prostate tissue. The amount of
total RNA obtained was high enough to directly check the quality
of the preparation by spectrophotometry, followed by convention-
al electrophoresis. Only good quality RNA was used for RT-
qPCR analysis. Eight informative genes plus 2 housekeepers were
analysed starting from the same RNA sample.
RT q-PCR and data analysis
Relative quantification of the target genes was performed with the
well known REST software tool [26]. Changes in the level of
expression of 7 out of 8 informative genes in CaP Versus benign
tissue did not reach statistical significance (not shown), while CLU
was significantly down-regulated in CaP (p,0.05). In Figure 2, the
relative gene expression of the signature obtained by the 2‘2DDCT
method is reported as a function of RP final Gleason score.
Interestingly, CLU is significantly and reversely related (p,0.01) to
the Gleason score of the tumour: i.e. lower expression levels of CLU
were found in higher Gleason score specimens. In Table 2 are shown
the final results of classification using the Nearest Neighbour (NN)
Gene Signature
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classifier combined with the 10-fold cross validation. Although the
REST analysis showed that only the changes in CLU expression were
statistically significant, NN classification+10-fold cross validation
performed on DCt data revealed a very good performance, in that
the discrimination of CaP versus benign specimens was obtained
with a combination of 7 genes (H3, GAS1, SSAT, CLU, AdoMetDC,
Table 1. complete list of clinical cases with clinical data at radical RP and final pathological or molecular classification with Leave-
One-Out cross validation procedure in order to obtain a unique classification for each sample.
Patient # Age
PSAtot
(ng/ml)
Gleason score
(whole gland)
Pathological
diagnosis of tissue
specimen 1:
Molecular
diagnosis tissue
specimen 1:
Pathological
diagnosis of tissue
specimen 2:
Molecular
diagnosis tissue
specimen 2:
1 68 2,8 G2 score4 BENIGN BENIGN
2 66 4,72 G3 score5 BENIGN BENIGN
3 62 3,07 BENIGN BENIGN
4 76 5,74 G3 score6 BENIGN BENIGN CaP 15% CaP
5 72 11,9 BENIGN BENIGN CaP 80% CaP
6 69 38,82 BENIGN CaP CaP 25% BENIGN
7 61 6,32 CaP 50% CaP CaP 5% CaP
8 68 6,90 BENIGN BENIGN CaP 40% BENIGN
9 67 10,8 BENIGN BENIGN
10 64 4,42 BENIGN BENIGN
11 73 4,28 BENIGN BENIGN
12 72 3,72 BENIGN BENIGN
13 64 4,21 BENIGN BENIGN
14 71 6,39 BENIGN CaP CaP 65% CaP
15 68 8,53 BENIGN BENIGN CaP 15% CaP
16 75 8,16 BENIGN BENIGN CaP 5% BENIGN
17 64 4,2 G3 score7 BENIGN BENIGN
18 59 15,07 G4 score7 BENIGN BENIGN CaP 25% CaP
19 67 49,30 BENIGN BENIGN CaP 5% CaP
20 65 19,70 BENIGN BENIGN CaP 90% CaP
21 68 9,75 BENIGN BENIGN CaP 25% CaP
22 67 9,1 CaP 5% CaP CaP 90% CaP
23 74 12,1 CaP 25% CaP CaP 40% CaP
24 68 12 BENIGN BENIGN CaP 90% CaP
25 64 5,97 BENIGN CaP
26 71 9,04 BENIGN BENIGN
27 61 9,6 CaP 85% CaP
28 77 17,7 CaP 90% CaP
29 70 11,26 BENIGN CaP CaP 5% CaP
30 62 4,35 BENIGN BENIGN
31 72 4,5 BENIGN BENIGN CaP 10% BENIGN
32 72 6,55 G4 score8 BENIGN BENIGN CaP 20% CaP
33 60 11,7 BENIGN BENIGN
34 71 5,6 BENIGN CaP CaP 5% CaP
35 53 11,10 G5 score8 BENIGN BENIGN CaP 55% CaP
36 65 5,04 BENIGN BENIGN CaP15% CaP
37 66 5,2 BENIGN CaP CaP 5% CaP
38 71 16,8 BENIGN CaP CaP 30% CaP
39 70 4,68 CaP 15% CaP
40 65 7,78 G5score9 BENIGN BENIGN CaP 10% BENIGN
41 72 10,8 BENIGN BENIGN CaP 85% CaP
Mean age of the patients was 66.865.7. Mean PSA value at RP was 10.268.7 ng/mL. Gleason score is given by examination of the whole gland (fixed and embedded)
after RP. Pathological evaluation of the frozen sections is indicated, together with percent of cancer cells given as a mean of pre- and post-RNA frozen sections. 44/66
were CaP-benign paired specimens obtained from the same patient. Specimens misclassified by the molecular method are in bold italic.
doi:10.1371/journal.pone.0003617.t001
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OAZ, ODC), using 3 neighbours and the correlation-based distance.
This classification is statistically significant.
In this work we paid the highest attention to realize the best
possible quality of tissue sampling and characterization (Figure 1).
This is absolutely required giving the high heterogeneity of a
prostate cancer specimen. The combination of a ‘‘robust’’ and
widely tested approach for statistical analysis of data with high
quality specimen sampling allowed us to obtain the final validated
result with a dataset of 66 specimens.
The concordance between our gene signature classification and
final pathological classification (CaP versus benign) obtained by
the pathologist was (8065)%, with a sensitivity of (8166)% and a
specificity of (7867)%. Tissue specimens that have been
misclassified by the molecular method, with respect to pathological
classification, are indicated in Table 1 (bold). We remark that in
this case a Leave-One-Out cross validation has been considered,
since with the N-fold procedure misclassifications of single samples
may vary at each realization. With the same combination of genes
we correctly sub-classified 84% of tumour specimens with regard
of patient’s age, 71% with regard to final RP Gleason score and
42% with regard to PSA before RP (Table 2). The same signature
did not perform well for classification with regard to TNM staging.
Inter-laboratory validation methodology
A second laboratory was participating in an inter-lab validation
methodology. Each tissue specimen was analyzed individually,
determinations were in duplicate wells and each experiment was
run for 6 times in both independent laboratories, with Ct line set at
the same value. Inter-laboratory variability was less than 1 cycle
for each single determination. (data not shown). Such variability
did not affect significantly final classification.
As little as 1 mg of cancer tissue within 20 mg of benign
specimen was detected
As shown in Table 1, the amount of cancer tissue was only 5%
in 7/31 specimens (equal to 22.5% of total specimens; 6/7 have
been correctly classified), and less than 15% in 13/31 specimens
(equal to 42% of total specimens; 10/13 have been correctly
classified). Therefore, the relative cancer tissue component
accounted for only about 1–3 mg of tissue out of 20 mg total.
Table 1 provides a complete list of the clinical cases from which
each tissue specimen was obtained, also including clinical data,
classification by the pathologist and percent of cancer cells present
in the specimen, expressed as a mean value between the pre- and
the post-RNA sections (see Figure 1).
Discussion
Identification of novel and accurate molecular
biomarkers: the challenge
The identification of novel and accurate biomarkers for reliable
molecular diagnosis of CaP is a real challenge. Previous studies by
DNA microarray have identified molecular signatures that
significantly correlated with CaP progression [27] or grading
[28], leading to identification of informative genes (sometimes with
unknown functions) that are still awaiting further studies for
elucidating their role in CaP progression [29]. Other successful
studies resulted in molecular diagnosis of CaP, but they were only
Figure 1. Sandwich procedure developed for collection of
specimens and direct comparison of morphological and
molecular classification.
doi:10.1371/journal.pone.0003617.g001
Figure 2. Relative gene expression (cancer versus benign) as a function of RP Gleason score. * p value,0.01 (t-test). White bars =Gleason
score,7; Grey bars =Gleason score$7. Error bars represent the standard error of the mean.
doi:10.1371/journal.pone.0003617.g002
Table 2. Final results of classification using the Nearest
Neighbour (NN) classifier.
DICHOTOMIES DISCRIMINATED % CORRECT CLASSIFICATION
CaP vs Benign (8065)
Age: #65 vs .65 84
Gleason score: ,7 vs $7 71
PSAtot (ng/mL): ,10 vs $10 ng/mL 42
The 10-fold cross validation procedure was used in order to estimate the mean
performance of the signature and the confidence interval. CaP versus benign
specimens were discriminated with (8065)% accuracy, (8166)% sensitivity and
(7867)% specificity. The result is expressed as mean695% confidence interval,
approximately corresponding to 2 standard deviations.
doi:10.1371/journal.pone.0003617.t002
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based on few selected, cancer-specific genes. PCA3 is the best
single CaP predictor: it is highly specific, but the sensitivity is
relatively low [30]. Moreover, the sensitivity did not improve even
when two more prostate-related genes were added [24,25].
A novel and reliable method based on a robust approach
Our work provides a reliable method for the molecular diagnosis
of CaP that takes advantage of a relatively simple method. The 7-
gene model here presented is based on the determination of genes
which are known to be expressed in both benign and cancer tissue,
and subjected to high individual variation. Therefore, the novelty of
our approach consist in achieving efficient molecular classification of
CaP with regard to final pathological diagnosis without using genes
that are specifically highly up- or down-regulated in benign versus
cancer tissue. In fact, our work is based on the detection and analysis
of the expression of genes which are long time known to be
physiologically expressed as well as essential for the biology of
prostate cells. For instance, aliphatic polyamines are produced at
very high levels by prostate epithelial cells and then released in
prostate fluid in mM amounts [31–33], although the precise role of
these compounds is still unknown. Detection of polyamines in urine
was already attempted long time ago for the diagnosis of CaP [34].
To achieve a reliable detection of our gene signature in cancer
tissue specimens and to implement practical use we had to address
several technical issues. In absence of any dedicated specific tool or
instrument, the development of a ‘‘sandwich’’ procedure was
necessary for obtaining morphological and molecular data from
the same tissue specimens (Figure 1).
Statistical analysis
In previous publications, working with both animal [14] and
human [3,4] CaP models we have demonstrated strictly related shifts
in the expression of all genes studied. Nevertheless, the REST
analysis showed that the relative expression of 7 genes besides CLU
did not reach statistical significance in malignancy. This was
somehow unexpected. The difficulty of pursuing a molecular
approach to CaP diagnosis in the real clinical setting is evident.
But this result is explained by the fact that polyamine genes
expression are known to be characterized by high individual
variation in the tissue specimens analysed. Nevertheless, this did
not jeopardize our analysis, because the molecular classification of
tissue specimens here presented takes into consideration the whole
gene signature, detecting a significant difference in the entire gene
expression profile regardless of individual variations. The final result
is that the integrated pattern of expression is significantly different in
CaP versus benign controls. This novel approach has been successful
using the NN classifier, a statistical method known to perform well
specifically for cancer classification even when compared with other
sophisticated methods [35,36]. NN is a nonparametric method that
belongs to the class of ‘‘robust’’ classifiers [37]. NN is well known to
render a good performance where the boundary between the two
classes to be discriminated is not clear-cut from the geometric point
of view. This condition often happens in clinical studies in which
individual variations may be much higher as compared to laboratory
samples obtained from in vitro experiments, providing ‘‘fuzzy’’
boundaries which might result from complex gene expression
profiles. NN is virtually not sensible to limited sampling of the classes
to be discriminated because of the very limited number of
parameters (namely, the choice of the distance function and the
number of neighbours). Nevertheless, NN renders very good
classification performances also compared to other multiparametric
well known classifiers like Neural Networks or Support Vector
Machines, methods that achieve optimal performance only when
large datasets are available.
To date, the best approach to reach a final evaluation on the
performance of even a ‘‘robust’’ statistical classifier such as NN is to
reuse the collected data both for the training and the validation of the
chosen classifier: this procedure is commonly referred to as cross
validation (well described in many "classical" statistical books [37]). In
N-fold cross validation, the dataset is randomly divided into N parts
and each part is used as a validation set using the other as training set.
Under these working conditions the classifier performance varies for
each random realization. We applied this procedure both with a 5-
fold (not shown) and a 10-fold cross validation, and obtained similar
performances. Because of the above considerations, the result
obtained by NN+10-fold cross validation procedure can be
considered as very reliable even with a small-size dataset. The same
statistical approach has been used already to analyze and validate
gene expression signatures in cancer research [38,39].
Under these conditions, the best classification performance was
obtained with a 7-gene model (H3, GAS1, SSAT, CLU, AdoMetDC,
OAZ and ODC). The concordance between molecular and final
pathological classification had an accuracy (8065)% with a sensitivity
of (8166)% and a specificity of (7867)%. This result demonstrates
that diagnosis of CaP by molecular data alone is feasible.
The gene signature detects very few cancer cells: the
cancer field effect
Notably, our method showed a very high sensitivity working on a
collection of CaP tissue specimens in which a significant portion of
the total, namely 7/31, were considered CaP on the basis of having
only 5% of cancer cells. This accounts for only 1 mg of cancer tissue
present in a total of 20 mg. A rationale consequence of this result is
that molecular events detected in pre-malignant tissue or in tissues
adjacent to cancer have provided diagnostic information, supporting
the hypothesis that a molecular approach for CaP diagnosis would
be a more sensitive and powerful tool than morphological
examination. This result is consistent with the ‘‘cancer field effect’’,
as recently hypothesized. According to this idea, transformed cells
extend beyond morphologically evident tumour. These events would
precede development of malignancy, because normal appearing
prostate tissue can undergo genetic changes in response to, or in
expectation of, morphologic cancer [40]. Recently, field effects based
on epigenetic events [41], nuclear matrix alterations [42], androgen
receptor immunoreactivity in the stroma surrounding cancer lesion
[43] have been discovered. Using oligonucleotide microarrays,
another confirmation derived by a study in which the expression
profiles of primary prostate cancer, adjacent normal tissue and
normal tissue from tumour free donors were compared [44]. This
scenario reinforce the requirement for objective molecular biological
markers of the aggressive phenotype to resolve uncertainties with
respect to identification of those precursor lesions which are most
likely to progress to invasive and metastatic prostate cancer. The
most likely explanation for misclassification between molecular and
morphological data obtained in our study is that very early molecular
changes may precede alteration of morphology, and therefore these
conditions would not overlap (or be associated with) the pathological
response. Molecular changes preceding changes in phenotype would
be detected by the molecular method for diagnosis, increasing its
sensitivity and explaining why 7 specimens (Table 1, bold) were seen
as cancer by the gene signature method, while the pathological
classification was benign. In this regard, higher sensitivity of the
method would result in reducing the number of samples that need to
be taken, with a clear advantage for the patient. It is known that
sensitivity of biopsy is a potential problem, explaining why saturation
biopsies have to be taken from patients. The procedure of saturating
the prostate with biopsies according to volume to maintain a
constant density of probing was developed in order to improve CaP
Gene Signature
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detection rate, and prostate biopsies are more and more often
becoming saturation biopsies [45]. Saturation biopsy can be
considered for patients at risk of cancer who are willing to accept
the side effects, but it is known that clinically insignificant cancers can
be detected [46].
On the other hand, the same rationale might also explain the
opposite result. In fact, the link between morphological lesions (i.e.
HG-PIN) and clinical CaP is still a matter of debate [47,48]. Also
PIN represents a ‘‘field effect’’ with a potential for cancer
progression, but may be not directly involved in or may not lead
to the development of invasive prostate cancer [49]. Therefore we
might hypothesize that certain changes in morphology might not
compulsory be associated to clinically relevant cell transformation.
Thus, specimens classified as benign by the molecular tool, but
cancer instead by the pathologist because of altered morphology (5/
31, Table 1, bold italic), might actually be different morphological
entities or clinically indolent lesions, possibly undergoing regression
because surrounded by reacting tissue. If so, this material would be
not significant from the clinical point of view, but clearly
distinguishable on a molecular basis from aggressive disease,
although we have no definitive evidence of this at the moment.
Clusterin and prostate cancer
CLU was cloned, sequenced and identified as the major up-
regulated gene during massive induction of apoptosis and prostate
regression caused by androgen depletion [7] or administration of
Finasteride [50] and vitamin D analogues [51,52]. The glycosy-
lated, extracellular form of CLU is produced at high basal level by
prostate cells and secreted in the prostate fluid, although its
possible role in reproduction is still puzzling the researchers [53].
Authors have proposed that CLU might be over-expressed in
cells surviving apoptosis, and not in cells doomed to die. Thus, a
cytoprotective role for CLU has been proposed [54]. The debate
on this issue is still wide open. It has been recently shown that
different protein forms can be originated from the same gene by
still unknown mechanisms [8]. TGF-beta and X-ray treatment
induce a truncated form of CLU that localizes to the nucleus [55–
58]. It is believed that different forms of CLU have different roles
in human cells [8], also depending by their sub-cellular
localization. Structural information concerning such protein forms
are still scarce. Data concerning the possible involvement of CLU
in transformation and tumour growth are still unclear or
contradictory in the literature.
The REST relative expression analysis demonstrated (data not
shown) that the down-regulation of CLU in CaP specimens is
statistically significant (p = 0.023). This is consistent with our
previous results [3,13]. Although the specific issue of whether CLU
is up- or down-regulated in CaP is still controversial [3,13,15,59–
61], confirmatory data supporting our hypothesis that CLU is not
only down-regulated in CaP, but also in the most of cancers, can
be easily retrieved from the Oncomine web site that collects data
from more than 20,000 independent microarray experiments
(http://www.oncomine.org). We have previously suggested that
CLU might be a potential tumor-suppressor gene [51] acting
through its nuclear form nCLU [57,63,64].
Potential prognostic value of the method
We previously found that our informative genes have prognostic
value [3,4]. It is known that Gleason score is the best single
predictor of CaP prognosis [65], but prediction of outcome in the
6–7 score range, comprising the most of clinical cases, is not
satisfactory [65]. We had 28/41 of patients in these conditions in
our bio-bank (Table 1). Unfortunately this analysis, as done before
[4], requires definitive outcome data on the whole cohort of
patient, and thus a minimum of a 5-year follow-up study will be
necessary as previously done [4]. We are strongly encouraged to
pursue this possibility because our informative genes have been
already found of prognostic value not only in human CaP [4], but
also in the TRAMP mice model. These animals were treated with
Green Tea Catechins (GTCs) for inhibition of CaP progression
[19]. In this experimental model, our gene signature was capable
to efficiently discriminate CaP tissue specimens of TRAMP mice
responding to GTCs treatment from those not-responding,
therefore suggesting that the biological behaviour of CaP might
be successfully investigated also in humans by the same approach.
In Table 2 it is also shown that the combination of 7 genes (H3,
GAS1, H3, SSAT, CLU, AdoMetDC, OAZ, ODC) correctly classified
84% of cancer specimens with regard to age of the patient, 71%with
regard to RP Gleason score and 42% with regard to PSA.
Misclassification with regard to PSA was actually expected, because
PSA is not a prostate tumour but, more properly, a prostate tissue
specific marker. As a matter of fact, also PSA cut-off values and CaP
detection rates are still a matter of debate [1]. Instead, we got a very
good performance on classification of age and Gleason score, both
widely used for clinical management of patients, with Gleason score
being the best predictor [65]. Also these results strongly suggest that
our approach is detecting important biological events occurring
during prostate cell transformation and cancer progression.
For the above reasons it will be fundamental to continue this
study by collecting clinical follow-up data, with a particular focus
on misclassified cases, for re-classification of patients as a function
of final outcome and possible validation of the potential prognostic
power of the method.
Final remarks
In conclusion, the RT-qPCR gene profiling method based on
the gene signature described here appear to be an appropriate and
reliable tool for molecular diagnosis of presence/absence of CaP
not subjected to intra- and inter-observer error. This test could be
of help to enhance diagnosis and particularly in those cases in
which it is necessary to resolve possible uncertainties. Our
approach, based on detection of a multiparametric expression
signature, yielded the best performance at detection of CaP ever
published with single predictors as far as we know. The method
has potential prognostic value, because we previously demonstrat-
ed that the expression level of these genes correlate with the final
outcome of CaP patients. Future research should be conducted to
obtain the gene signature using less invasive means than a biopsy.
Materials and Methods
Prostate Tissue Specimens Collection/Handling and
Pathological Classification:
Ethical approval for this work was granted by local Hospital
Ethical Committee (Azienda Ospedaliera-Universitaria di Parma)
and informed written consent was obtained from patients involved.
Prostate surgical specimens were obtained from patients diagnosed
with CaP by biopsy and recommended to undergo RP. No
therapy was given to patients at any time before RP. Tissue
specimens were excised out from the prostate gland immediately
after surgery and quickly frozen in dry ice as previously described
[3]. Two tissue specimens were obtained from the same prostate
gland: one from the (supposed) cancerous portion of the gland,
according to prostate mapping by biopsy. The second one from
the (supposed) benign tissue taken very far away (i.e. in different
areas of the prostate, ideally in the opposite sextant) from the
neoplastic lesion. Both specimens were quickly frozen with dry ice
to preserve RNA integrity, then embedded in OCT and frozen-
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sectioned. Representative serial sections (7 mm-thick) were E&H
stained (Figure 1). Right after the last section (the so-called ‘‘pre-
RNA’’ frozen section), 10–12 frozen sections at 30 mm-thickness,
for a total of about 20 mg of tissue, were collected and stored at
280uC for RNA extraction. Then the cryostat was set back to
7 mm thickness and ‘‘post-RNA’’ frozen section were cut for E&H
staining. This ‘‘sandwich’’ procedure (Figure 1) rendered 2 frozen
sections with a thickness of 7 mm named ‘‘pre-RNA’’ and ‘‘post-
RNA’’. They were both used by the pathologist for the
pathological classification of the 300–350 mm-thick tissue speci-
men contained in between. This material was then used for RNA
extraction. Classification by the pathologist of the pre- and post-
RNA sections was two-fold: presence or absence of cancer. No
Gleason grade or score was given on these frozen sections because
morphology was not preserved by fixation. Thank to this
procedure we gained as much morphological information as
possible from the tissue specimen that was homogenized for
molecular analysis. For RT-qPCR analysis we only used CaP
specimens with a cancer cell content covering at least 5% of the
whole section area. Only specimens with no PIN lesions or tumour
invasion were used as controls (benign). We also collected clinically
relevant parameters: age of the patient, total serum PSA before
surgery. Final Gleason score of the tumour was assessed after
formalin fixation and pathological examination of the whole gland.
RNA extraction
Total RNA was extracted from 20 mg snap-frozen human tissue
specimens using RNA-fast (Molecular Systems, San Diego, CA)
according to the manufacturer protocol. After spectrophotometric
quantification, 2-mg aliquots were routinely electrophoresed on a 1%
agarose gel to check quality and integrity as previously described [3].
Retrotranscription
Two mg of total RNA from each sample was primed with 50 ng
of random hexamers (Invitrogen) and incubated at 42uC for
60 min in a 30 mL (final volume) reaction mixture containing
50 mM tris HCl pH 8.3, 75 mM KCl, 3 mM MgCl2, 10 mM
dithiothreitol, 0.5 mM dNTPs and 300 units of Superscript II
Reverse Transcriptase (Invitrogen).
Real-time PCR amplification
OnemLof each cDNApreparationwasPCR-amplified using the set
of primers described below. PCR conditions were: 95uC for 15 min
and then95uCfor30 s, 60uCfor30 s and72uCfor 30 s repeated for 40
cycles, then 95uC for 30 s and 55uC for 30 s. Melting curves were
obtained. RT-qPCR was performed on the DNA Engine Opticon 4
machine (MJ Research, Wathman, MA, USA) using a 26 SYBR
Green customized master mix (Biodiversity s.r.l., Brescia, Italy).
Primers:
GAS1 DIR: 59- CGC TGA GCC GCT ACC TGA -39
REV: 59- CTT GGG CAT AGC CAG CAT GT -39
H3 DIR: 59- CAG GAG GCT TGT GAG GCC TA -39
REV: 59- AGC TGG ATG TCT TTG GGC AT -39
SSAT DIR: 59 - GGT TGC AGA AGT GCC GAA AG -39
REV: 59- GTA ACT TGC CAA TCC ACG GG -39
CLU DIR: 59- TGA TCC CAT CAC TGT GAC GG -39
REV: 59- GCT TTT TGC GGT ATT CCT GC -39
ODC DIR: 59- AGA CCT TCG TGC AGG CAA TC -39
REV: 59- AGG AAA GCC ACC GCC AAT AT -39
AdoMetDC DIR: 59- CAT CAC TCC AGA ACC AGA AT -39
REV: 59- TAA CAA ACA AGG TGG TCA CA -39
OAZ DIR: 59- CCT CCA CTG CTG TAG TAA CC -39
REV: 59- GAA AGA TTG TGA TCC CTC TG -39
GAPDH DIR: 59- AAC CTG CCA AAT ATG ATG AC -39
REV: 59- TTG AAG TCA GAG GAG ACC AC -39
HMBS DIR: 59- TGA AAT CAT TGC TAT GTC CA -39
REV: 59- ATG TTC AAG CTC CTT GGT AA -39
PGK1 DIR: 59- CTT TCA TGT GGA GGA AGA AG -39
REV: 59- TAG CTT GGA AAG TGA AGC TC -39
RT-qPCR data analysis
Analysis of the relative expression of target genes was performed
with REST 2005 (Relative Expression Software Tool) BETA
V1.9.9. [26]. Two housekeeper genes phosphoglycerate kinase 1
(PGK1) and hydroxy-methyl-bilane synthetase (HMBS) were used
in the study. Also primers efficiency was calculated and used for
REST analysis.
Statistical Analysis
Raw Ct data were normalized and transformed in DCt by using
the geometric mean of both housekeepers (PGK1 and HMBS).
Normalized DCt data were used for classification. The NN
classifier was used in order to discriminate CaP from benign tissue.
The 10-fold crossvalidation procedure was used for final validation
in order to reduce the underestimation of the misclassification
error due to over-fitting. All the possible combinations of the 8
genes, several numbers of neighbours and different distances
between sample profiles (Euclidean distance, Correlation-based
distance, Mahalanobis distance) were considered in the analysis.
The same procedure was used for sub-classification of CaP
specimens into several dichotomies: patients whose age was #65
versus .65; total PSA value at prostatectomy ,10 versus $10;
final Gleason score on fixed whole prostate gland ,7 versus $7.
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